Supply of Amoxycillin and Clavulanic Acid 125 mg tablet strip pack by Sandoz Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure their safety, quality, and efficacy. One of its key provisions is the issuance of consents for the supply of therapeutic goods that do not fully conform to the standards outlined in Therapeutic Goods Orders. This mechanism allows for flexibility in the regulatory framework, enabling the supply of such goods under specific conditions to meet public health needs. The 2013 notice issued by the delegate of the Secretary of the Department of Health and Ageing under sections 14 and 14A of the Act demonstrates the application of this regulatory flexibility. This consent was granted to Sandoz Pty Ltd to supply certain products that did not conform to the specified labelling requirements, subject to conditions designed to mitigate any potential risks associated with the non-conformance. The policy objective in this instance is to facilitate the availability of essential therapeutic goods while maintaining the overarching goal of protecting public health.

Scope and Application

The Therapeutic Goods Act 1989, as referenced in section 14 and 14A, provides the legislative framework governing the regulation of therapeutic goods in Australia. This Act applies to all therapeutic goods, including medicines, medical devices, and blood and blood components, ensuring they meet specific safety, quality, and efficacy standards. It encompasses both the supply and advertising of therapeutic goods, applying to entities such as pharmaceutical companies, healthcare providers, and distributors within Australia’s jurisdiction. The Act's reach is national, as it operates under the Commonwealth, thereby affecting all states and territories. However, it does not explicitly state exclusions, exemptions, or specific thresholds within the provided excerpt, and its application can be extended or restricted through subordinate instruments such as regulations or orders. The consent given for the supply of specific products by Sandoz Pty Ltd, subject to certain conditions, exemplifies the Act's function in regulating therapeutic goods at a detailed level, ensuring compliance with approved standards and conditions for specific products.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in the Gazette notice (C2013G00214), pertains to specific provisions allowing for the supply of certain pharmaceutical products under certain conditions. Section 14(1) of the Act allows the delegate of the Secretary of the Department of Health and Ageing to consent to the supply of therapeutic goods that do not fully conform to approved standards, while Section 14A imposes conditions on such consent to ensure public safety and compliance with health regulations. In this instance, the consent (Section 14(1)) was given for Sandoz Pty Ltd to supply two specific products: amoxycillin (as trihydrate) and clavulanic acid (as potassium) in two different dosages (CURAM DUO FORTE 875/125 and CURAM DUO 500/125). The products in question do not comply with paragraphs 3(2)(a) and 3(2)(b) of Therapeutic Goods Order 69, particularly concerning the naming of active ingredients on the carton labels. The obligations imposed on Sandoz Pty Ltd by this Act include adherence to the specified conditions of consent. These conditions mandate that the carton labels used must be identical to those provided in the company’s correspondence dated November 15, 2012, and that no other changes are to be made to the products listed. This ensures that the products supplied maintain a level of consistency and traceability, crucial for quality control and public safety. Additionally, the consent is strictly time-bound, applying only until June 30, 2013, after which the products must conform to all relevant regulations without any further exceptions. Failure to comply with the conditions of consent or the provisions of the Therapeutic Goods Act 1989 may result in legal repercussions. The Act does not explicitly state the offences or penalties for breaches of consent conditions within this specific notice; however, under general provisions of the Act, breaches can lead to criminal or civil penalties. Typically, penalties for non-compliance may include fines and, in severe cases, imprisonment. The exact penalties would be determined based on the specific breach and the court's discretion. It is important for Sandoz Pty Ltd to adhere strictly to the terms of the consent to avoid any legal consequences.